David R. Foster
B.S., Pharmacy, Wayne State University, 1997
Pharm.D., Wayne State University, 1999
Postdoctoral Fellowship, Critical Care, University of Michigan, 1999-2002.
Dr. Foster's research interests are focused on the study of alterations in drug and nutrient disposition and drug effects in critically ill patients. Current research includes evaluation of changes in intestinal permeability to xenobiotics in critical illness. Specifically, this research involves the investigation of alterations in drug and nutrient absorption by passive and active transport mechanisms, and the molecular mediators underlying these changes in burn injury and sepsis. A related area of research is the use of natural anti-inflammatory compounds to attenuate inflammation-related changes in intestinal function. Other interests include the study of the contribution of active transport processes to variability in drug disposition in a number of patient populations. Dr. Foster's clinical interests are focused the provision of pharmacotherapy to critically-ill patients, with an emphasis on burn and trauma patients.
Dr. Foster is a member of the American College of Clinical Pharmacy, the Society of Critical Care Medicine, the American Society for Parenteral and Enteral Nutrition, the American Society for Clinical Pharmacology and Therapeutics, the American Association of Colleges of Pharmacy, and the Indiana College of Clinical Pharmacy. Dr. Foster is an elected fellow of the American College of Clinical Pharmacy.
Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet. 2015;54:783-95.
Johnson BL, Damer KM, Walroth TA, Buening NR, Foster DR, Sood R. A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients. J Burn Care Res. 2014 (e-pub ahead of print).
Pergolizzi JV, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R, Summers KH. The prevalence of opioid-related major potential drug-drug interactions and their impact on healthcare costs in chronic pain patients. Journal of Managed Care Pharmacy. 2014;20:467-476.
Nader AM and Foster DR. Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity. The Journal of Clinical Pharmacology. 2014;54:3-13.
Overholser BR and Foster DR. Improving Outcomes with Opioid Use: Focus on Pharmacokinetic Drug-Drug Interactions. The American Journal of Managed Care. 2011;17:S276-S287.
Overholser BR, Foster DR, Henry JR, Plake KS, Sowinski KM. Development and assessment of an introductory clinical research course delivered as an elective in a Doctor of Pharmacy curriculum. American Journal of Pharmaceutical Education. 2010;74:9;165.
Lat I, Foster DR, Erstad B. Drug-induced acute liver failure and gastrointestinal complications. Critical Care Medicine. 2010;38: 6 (suppl): S175-S187.
Foster DR, Gonzales JP, Amidon GL, Welage LS. Intestinal dipeptide absorption is preserved during thermal injury and cytokine treatment. JPEN: Journal of Parenteral and Enteral Nutrition. 2009;33:520-528.
Foster DR, Yee S, Bleske BE, Carver PL, Shea MJ, Menon SS, Ramachandran C, Welage LS, Amidon GL. Lack of interaction between the peptidomimetic substrates captopril and cephradine. Journal of Clinical Pharmacology. 2009;49:360367.
Foster DR, Landowski CP, Zheng X, Amidon GL, Welage LS. Interferon-gamma increases expression of the di/tri-peptide transporter, h-PEPT1, and dipeptide transport in cultured human intestinal monolayers. Pharmacological Research. 2009;59:215-220.
Huang R, Murray DJ, Foster DR. Role of xenobiotic efflux transporters in resistance to vincristine. Biomedicine and Pharmacotherapy. 2008;62:59-64.
Foster DR, Sowinski KM, Chow HHS, Overholser BR. Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions. Therapeutic Drug Monitoring. 2007;29:835-842.
Foster DR, Zheng X. Cephalexin inhibits N-formylated peptide transport and intestinal hyperpermeability in Caco2 cells. Journal of Pharmacy and Pharmaceutical Sciences. 2007;10:330-341.
Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochemical Pharmacology. 2006;17:1695-1704.
Neudeck BL, Foster DR, Li L, Gonzales JP, Welage LS. The effects of thermal injury on transcellular permeability and intestinal p-glycoprotein in rats. Burns. 2003;29:803-809.
Landowski CP, Sun D, Foster DR, Menon SS, Ramachandran C, Welage LS, Amidon GL. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. Journal of Pharmacology and Experimental Therapeutics 2003;306:778-786.
Sun D, Lennernas H, Welage L, Barnett J, Landowski C, Foster DR, Fleisher D, Lee KD, Amidon GL. A Comparison of Human and Caco2 Gene Expression Profiles for 12,000 Genes and the Permeabilities of 26 Drugs in the Human Intestine and Caco-2 Cells. Pharmaceutical Research. 2002;19:1400-1416.